prikaz prve stranice dokumenta Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
  Download
PDF 946.74 KB
Scientific paper - Review paper
Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
Pharmaceutics, 13 (2021), 9; 1481. https://doi.org/10.3390/pharmaceutics13091481
Primorac, Dragan; Čemerin, Martin; Matišić, Vid; Molnar, Vilim; Strbad, Marko; Girandon, Lenart; Zenić, Lucija; Knežević, Miomir; Minger, Stephen; Polančec, Denis

Linked objects
COVID-19 | Virtual collection
Cite this document

Primorac, D., Čemerin, M., Matišić, V., Molnar, V., Strbad, M., Girandon, L. ... Polančec, D. (2021). Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. Pharmaceutics, 13. (9). doi: 10.3390/pharmaceutics13091481

Primorac, Dragan, et al. "Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment." Pharmaceutics, vol. 13, no. 9, 2021. https://doi.org/10.3390/pharmaceutics13091481

Primorac, Dragan, Martin Čemerin, Vid Matišić, Vilim Molnar, Marko Strbad, Lenart Girandon, Lucija Zenić, Miomir Knežević, Stephen Minger and Denis Polančec. "Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment." Pharmaceutics 13, no. 9 (2021). https://doi.org/10.3390/pharmaceutics13091481

Primorac, D., et al. (2021) 'Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment', Pharmaceutics, 13(9). doi: 10.3390/pharmaceutics13091481

Primorac D, Čemerin M, Matišić V, Molnar V, Strbad M, Girandon L, and sur.. Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. Pharmaceutics [Internet]. 2021 September 16 [cited 2024 May 06];13(9). doi: 10.3390/pharmaceutics13091481

D. Primorac, et al., "Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment", Pharmaceutics, vol. 13, no. 9, September 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:165701. [Accessed: 06 May 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
AuthorDragan Primorac
AuthorMartin Čemerin
AuthorVid Matišić
AuthorVilim Molnar
AuthorMarko Strbad
AuthorLenart Girandon
AuthorLucija Zenić
AuthorMiomir Knežević
AuthorStephen Minger
AuthorDenis Polančec
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titlePharmaceutics
Numberingvol. 13, no. 9, 1481
e-ISSN1999-4923
DOIhttps://doi.org/10.3390/pharmaceutics13091481
URN:NBNurn:nbn:hr:184:165701
Publication2021-09-16
Document URLhttps://www.mdpi.com/1999-4923/13/9/1481
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2021-12-03 11:26:40